Back to today’s briefing

Story perspectives

AstraZeneca Launches FluMist for Easy Self-Administered Vaccination

8/15/2025

50 7

Summary

Story summary

AstraZeneca introduced FluMist Home, enabling U.S. residents to self-administer nasal flu vaccines, increasing accessibility.
The FDA approved FluMist for adults aged 18-49 and children aged 2-17 to boost vaccination rates.
FluMist's effectiveness is similar to traditional flu shots and is delivered in temperature-controlled packaging.
Experts stress the need for flu vaccinations due to recent declines in immunization rates and severe flu seasons.

1 of 1

Story summary

AstraZeneca introduced FluMist Home, enabling U.S. residents to self-administer nasal flu vaccines, increasing accessibility.
The FDA approved FluMist for adults aged 18-49 and children aged 2-17 to boost vaccination rates.
FluMist's effectiveness is similar to traditional flu shots and is delivered in temperature-controlled packaging.
Experts stress the need for flu vaccinations due to recent declines in immunization rates and severe flu seasons.